medicine-news-1/nuvo-announces-2009-second-quarter-financial-results-53966-5/;/a><br

Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2 Vivakor Confirms Record Date of Stock Dividend 3 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2 Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3 Reportlinker Adds Neurostimulation - A Global Market Perspective 2 Reportlinker Adds Neurostimulation - A Global Market Perspective 3 Reportlinker Adds Neurostimulation - A Global Market Perspective 4 Reportlinker Adds Neurostimulation - A Global Market Perspective 5 Reportlinker Adds Neurostimulation - A Global Market Perspective 6

[0] Vivakor Confirms Record Date of Stock Dividend [0] Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope [0] Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock [0] Reportlinker Adds Neurostimulation - A Global Market Perspective

Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5 Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2 Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3 HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 1 HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 2 Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 1 Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 2 Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 3 Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 4 Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1 Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2 Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3 Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4

[0] Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting [0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease [0] Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million